Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
HIV Medicine|April 20, 2016
Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavirJ Rojas, M Lonca, A Imaz, et al.
Nutrients|July 28, 2026
Olive Oil as a Modulator of Gut Microbiota and Intestinal Health: A Narrative Review from Microbial Metabolism to Host ResponsesLuna Barrera-Chamorro, Teresa Gonzalez-de la Rosa, Jose L Del Rio-Vazquez, et al.
Food & Function|May 14, 2026
Oleic and omega-3 fatty acids buffer neuroinflammation in a scopolamine model with Alzheimer's-like features via target-level interactionsMarlua Albertuni, Maria Torrecillas-Lopez, Teresa Gonzalez-de la Rosa, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 8, 2025
Neuroavailable peptides from hempseed protein hydrolysates reduce hippocampal inflammation and glial activation in a scopolamine-induced Alzheimer's diseaseMaria Torrecillas-Lopez, Carmen M Claro-Cala, Teresa Gonzalez-de la Rosa, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 25, 2020
Trabecular and cortical bone involvement in rheumatoid arthritis by DXA and DXA-based 3D modellingM L Brance, B A Pons-Estel, N J Quagliato, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 1998
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexesR M Lavinsky, K Jepsen, T Heinzel, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|November 30, 2013
Reduction of early reperfusion injury with the mitochondria-targeting peptide bendaviaDavid A Brown, Sharon L Hale, Christopher P Baines, et al.
Journal of Translational Medicine|January 28, 2025
FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitisAmaya Lopez-Pascual, Eva Santamaria, Nuria Ardaiz, et al.
Clinical Science (London, England : 1979)|September 20, 2024
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)Amaya Lopez-Pascual, Joan S Russo-Cabrera, Nuria Ardaiz, et al.
Journal of the American College of Cardiology|November 11, 2025
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label TrialNeal K Lakdawala, Ray E Hershberger, Pablo Garcia-Pavia, et al.
Pageof 10